Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (1): 49-52. doi: 10.19723/j.issn.1671-167X.2019.01.009

• 论著 • 上一篇    下一篇

手术联合 125I粒子治疗口腔颌面部腺样囊性癌的疗效与相关预后因素分析

李聪,刘树铭,郑磊,黄明伟,石妍,吕晓鸣,张建国,张杰()   

  1. 北京大学口腔医学院·口腔医院,口腔颌面外科 国家口腔学研究中心 口腔数字化医疗技术和材料国家工程实验室 口腔数字医学北京市重点实验疾病临床医室,北京 100081
  • 收稿日期:2018-10-11 出版日期:2019-02-18 发布日期:2019-02-26
  • 通讯作者: 张杰 E-mail:zhangjie06@126.com

Study of surgery combined with 125I brachytherapy for adenoid cystic carcinoma of oral and maxillofacial region

Cong LI,Shu-ming LIU,Lei ZHENG,Ming-wei HUANG,Yan SHI,Xiao-ming LV,Jian-guo ZHANG,Jie ZHANG()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-10-11 Online:2019-02-18 Published:2019-02-26
  • Contact: Jie ZHANG E-mail:zhangjie06@126.com

RICH HTML

 10   

PDF (PC)

367

摘要：

目的:回顾总结北京大学口腔医院应用手术联合 125I放射性粒子治疗口腔颌面部腺样囊性癌的疗效,并分析相关预后因素。方法:75例原发性口腔颌面部腺样囊性癌患者,行原发灶扩大切除或部分切除,经治疗计划系统(treatment planning system,TPS)制定放射性粒子植入计划,于术中或术后植入放射性粒子,处方剂量60~120 Gy。患者定期随访,采用Kaplan-Meier法评估肿瘤控制及生存情况,并应用Cox回归分析对其相关预后因素进行分析。结果:75例患者3年、5年局部控制率分别为90.0%、78.8%,T1~T2患者分别为92.2%、82.0%,T3~T4患者均为82.6%。无瘤生存率为3年74.9%、5年54.3%。总生存率3年、5年分别为86.0%、79.6%,其中T1~T2患者均为91.3%,T3~T4患者分别为73.9%、59.7%。3年、5年无远处转移生存率分别为84.4%、76.7%,其中T1~T2患者分别为83.4%、79.6%,T3~T4患者分别为86.0%、67.8%。通过COX单因素分析及多因素分析,年龄是影响患者局部控制的预后因素,肿瘤分期及肿瘤部位为影响患者生存率的预后因素。结论: 125I放射性粒子植入作为口腔颌面部腺样囊性癌术后辅助治疗可以获得较好的局部控制率、无瘤生存率及总生存率。高龄者易出现局部复发,肿瘤分期高及肿瘤位于鼻腔、鼻窦者生存率较低。

关键词: 癌, 腺样囊性, 口腔肿瘤, 近距离放射疗法, 碘放射性同位素, 预后

Abstract:

Objective: To retrospectively analyze the results of treatment outcome by surgery combined with 125I brachytherapy and correlative factors of adenoid cystic carcinoma (ACC). Methods: In the study, 75 patients with primary ACC of oral and maxillofacial region were treated by surgery combined with 125I seeds brachytherapy. Radical resection or subtotal resection was applied for the tumor. The brachytherapy treatment planning system was used to create implant plans with the prescribed dose of 60 Gy to 120 Gy. The 125I seeds were implanted intraoperatively or postoperatively. The regular follow-up was required. The Kaplan-Meier method was used to assess the tumor control rate and the patients’ survival rates. Meanwhile, the Cox regression analysis was used to find out the prognostic factors. Results: Local control rates at the end of 3 and 5 years were as follows: T1-T2, 92.2% and 82.0%; T3-T4, 82.6% and 82.6%; and overall, 90.0% and 78.8%. The disease-free survival rates were 74.9% and 54.3%, respectively. The overall survival rates for all the patients were 86.0% and 79.6%, respectively at the end of 3 and 5 years and were 91.3% and 91.3% for T1-T2 patients vs. 73.9% and 59.7% for T3-T4 patients. Distant metastasis-free survival rates at the end of 3 and 5 years were 84.4% and 76.7%, respectively. The distant metastasis-free survival rates at the end of 3 and 5 years were 83.4% and 79.6% with T1-T2 lesion compared with 86.0% and 67.8% with T3-T4 lesion. According to the COX univariate analysis and multivariate analysis, the risk of local recurrence would be raised by the age. Tumor stage and tumor site were the prognostic factors of the overall survival rates. Conclusion: 125I brachytherapy conducted as an adjuvant therapy postoperatively of ACC of oral and maxillofacial region can acquire satisfactory local-regional control, distant metastasis-free survival, disease-free survival and overall survival. Tumors are prone to recur on the older patients. Patients having advanced tumor stage or tumor located in the nasal cavity or sinuses will suffer lower survival rates.

Key words: Carcinoma, adenoid cystic, Mouth neoplasms, Brachytherapy, Iodine radioisotopes, Prognosis

中图分类号: 

  • R739.8

表1

75例患者基本情况"

Items Data
Gender,n (%)
Male 21 (28)
Female 54 (72)
Age/years, median (range) 48.0 (18-74)
Follow-up time/months, median (range) 46.8 (0.4-111.0)
Tumor site,n (%)
Parotid glands 24 (32.0)
Submandibular glands 13 (17.3)
Sublingual glands 7 (9.3)
Palate 11 (14.7)
Mouth floor 11 (14.7)
Cheek 2 (2.7)
Tongue 3 (4.0)
Parapharyngeal 1 (1.3)
Other 3 (4.0)
T stage,n (%)
T1 22 (29.3)
T2 19 (25.3)
T3 2 (2.7)
T4 23 (30.7)
Not reported 9 (12.0)
N stage,n (%)
N0 64 (85.3)
N1 3 (4.0)
Not reported 8 (10.7)
Surgical margins,n (%)
Positive 14 (18.7)
Clear 61(81.3)
[1] Kokemueller H, Eckardt A, Brachvogel P , et al. Adenoid cystic carcinoma of the head and neck: a 20 years experience[J]. Int J Oral Maxillofac Surg, 2004,33(1):25-31.
doi: 10.1054/ijom.2003.0448 pmid: 14690656
[2] Zhang CY, Xia RH, Han J , et al. Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,115(3):368-375.
doi: 10.1016/j.oooo.2012.11.018 pmid: 23453028
[3] Tian Z, Li L, Wang L , et al. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6 982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010,39(3):235-242.
doi: 10.1016/j.ijom.2009.10.016 pmid: 19951834
[4] 于世凤, 高岩 . 口腔组织学与病理学[M]. 北京: 北京大学医学出版社, 2005: 307.
[5] Maciejewski A, Szymczyk C, Wierzgon J . Outcome of surgery for adenoid cystic carcinoma of head and neck region[J]. J Craniomaxillofac Surg, 2002,30(1):59-61.
doi: 10.1054/jcms.2001.0265 pmid: 12064885
[6] Garden AS, Weber RS, Morrison WH , et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995,32(3):619-626.
doi: 10.1016/0360-3016(95)00122-F pmid: 7790247
[7] Mendenhall WM, Morris CG, Amdur RJ , et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck[J]. Head Neck, 2004,26(2):154-162.
doi: 10.1002/hed.10380 pmid: 14762884
[8] Huang MW, Zheng L, Liu SM , et al. 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region [J]. Strahlenther Onkol, 2013,189(6):502-507.
doi: 10.1007/s00066-013-0324-3
[9] Takagi M, Demizu Y, Hashimoto N , et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014,113(3):364-370.
doi: 10.1016/j.radonc.2014.11.031 pmid: 25467004
[10] Chen AM, Bucci MK, Weinberg V , et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without post-operative radiation therapy: prognostic features of recurrence[J]. Int J Radiat Oncol Biol Phys, 2006,66(1):152-159.
doi: 10.1016/j.ijrobp.2006.04.014 pmid: 16904520
[11] Al-Mamgani A, van Rooij P, Sewnaik A , et al. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature[J]. Oral Oncol, 2012,48(3):278-283.
doi: 10.1016/j.oraloncology.2011.10.014 pmid: 22093375
[12] Jensen AD, Nikoghosyan AV, Poulakis M , et al. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival[J]. Cancer, 2015,121(17):3001-3009.
doi: 10.1002/cncr.29443 pmid: 26043145
[13] Casler JD, Conley JJ . Surgical management of adenoid cystic carcinoma in the parotid gland[J]. Otolaryngol Head Neck Surg, 1992,106(4):332-338.
doi: 10.1177/019459989210600403 pmid: 1314372
[14] Iseli TA, Karnell LH, Preston TW , et al. Facial nerve sacrifice and radiotherapy in parotid adenoid cystic carcinoma[J]. Laryngoscope, 2008,118(10):1781-1786.
doi: 10.1097/MLG.0b013e31817fae29 pmid: 18758382
[15] Iseli TA, Karnell LH, Graham SM , et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck[J]. J Laryngol Otol, 2009,123(10):1137-1144.
doi: 10.1017/S0022215109990338 pmid: 19573256
[16] van Weert S, Bloemena E, van der Waal I , et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period[J]. Oral Oncol, 2013,49(8):824-829.
doi: 10.1016/j.oraloncology.2013.05.004 pmid: 23751614
[17] Zheng L, Zhang JG, Zhang J , et al. Preliminary results of 125I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients [J]. Head Neck, 2012,34(10):1445-1449.
doi: 10.1002/hed.21955
[18] Zheng L, Zhang JG, Song TL , et al. 125I seed implant brachythe-rapy for the treatment of parotid gland cancers in children and adolescents [J]. Strahlenther Onkol, 2013,189(5):401-406.
doi: 10.1007/s00066-013-0313-6 pmid: 23519359
[19] 郭华秋, 刘树铭, 张杰 , 等. 老年头颈癌患者 125I粒子植入治疗后的生存质量研究 [J]. 中华放射医学与防护杂志, 2013,33(5):501-504.
doi: 10.3760/cma.j.issn.0254-5098.2013.05.011
[20] Lloyd S, Yu JB, Wilson LD , et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol, 2011,34(1):76-81.
doi: 10.1097/COC.0b013e3181d26d45
[21] 农晓琳, 陈琦, 黎燕宁 , 等. 63例涎腺腺样囊性癌患者预后相关因素的Cox模型分析[J]. 口腔医学, 2011,31(1):1-4.
[1] 周传香,周正,张晔,刘晓筱,高岩. 28例口腔基底样鳞状细胞癌的临床病理分析[J]. 北京大学学报（医学版）, 2022, 54(1): 62-67.
[2] 苏俊琪,宋扬,谢尚. 口腔鳞状细胞癌患者修复重建术后感染的病原学特征及感染风险预测模型的构建[J]. 北京大学学报（医学版）, 2022, 54(1): 68-76.
[3] 穆东亮,薛铖,安彬,王东信. 硬膜外阻滞与结直肠癌患者术后远期生存状态的关系:一项倾向性评分匹配的回顾性研究[J]. 北京大学学报（医学版）, 2021, 53(6): 1152-1158.
[4] 王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200.
[5] 高伟波,石茂静,张海燕,吴春波,朱继红. 显著高铁蛋白血症与噬血细胞性淋巴组织细胞增多症的相互关系[J]. 北京大学学报（医学版）, 2021, 53(5): 921-927.
[6] 张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报（医学版）, 2021, 53(5): 915-920.
[7] 田雨,程晓悦,贺慧颖,王国良,马潞林. 肾细胞癌合并尿路瘤栓的临床病理特征: 6例报道及文献回顾[J]. 北京大学学报（医学版）, 2021, 53(5): 928-932.
[8] 蒋艳芳,王健,王永健,刘佳,裴殷,刘晓鹏,敖英芳,马勇. 前交叉韧带翻修重建术后中长期临床疗效及影响因素[J]. 北京大学学报（医学版）, 2021, 53(5): 857-863.
[9] 庞泳,张沙,杨华,周柔丽. LAPTM4B-35蛋白作为肝癌血清学诊断新标志物的探讨[J]. 北京大学学报（医学版）, 2021, 53(4): 710-715.
[10] 肖若陶,刘承,徐楚潇,何为,马潞林. 术前血小板参数与局部进展期肾细胞癌预后[J]. 北京大学学报（医学版）, 2021, 53(4): 647-652.
[11] 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报（医学版）, 2021, 53(4): 686-691.
[12] 于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646.
[13] 孙争辉,黄晓娟,董靖晗,刘茁,颜野,刘承,马潞林. 临床T1期肾细胞癌肾窦侵犯的危险因素[J]. 北京大学学报（医学版）, 2021, 53(4): 659-664.
[14] 赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报（医学版）, 2021, 53(4): 665-670.
[15] 韩松辰,黄子雄,刘慧鑫,徐涛. 单侧肾细胞癌根治性切除术后的肾功能代偿[J]. 北京大学学报（医学版）, 2021, 53(4): 680-685.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报（医学版）, 2009, 41(2): 135 -140 .
[4] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[5] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[6] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[7] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[8] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报（医学版）, 2009, 41(5): 505 -515 .
[9] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报（医学版）, 2009, 41(5): 599 -601 .
[10] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部